Drugs in development · updated 30 October 2026
Famitinib: clinical trials and development status
As of 30 October 2026 Famitinib is in 20 active clinical trials (recruiting or ongoing, phases I–III) for 10 diseases. The most advanced phase is III.
Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Famitinib and get an email at every change or safety alert.
Sign in free →Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Triple-negative breast neoplasm | III | 5 | NCT05999149 |
| Breast neoplasm | III | 4 | NCT07382687 |
| Lung small cell carcinoma | II | 2 | NCT06306560 |
| Cholangiocarcinoma | II | 1 | NCT07847710 |
| Esophageal squamous cell carcinoma | II | 1 | NCT07796113 |
| Head and neck neoplasms | I–II | 1 | NCT07662681 |
| Melanoma | II | 1 | NCT07517653 |
| Ovarian neoplasm | II | 1 | NCT07355010 |
| Pancreatic neoplasm | II | 1 | NCT07814859 |
| Uterine cervix neoplasm | II | 1 | NCT07627620 |
Everything on Famitinib
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.